Benjamin Palleiko Sells 9,550 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 9,550 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $193,101.00. Following the completion of the transaction, the chief executive officer directly owned 462,577 shares of the company’s stock, valued at approximately $9,353,306.94. This represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $19.43 on Wednesday. The firm has a 50 day simple moving average of $17.59 and a 200-day simple moving average of $15.28. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a market cap of $995.20 million, a PE ratio of -4.92 and a beta of -0.40. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.83 and a 1-year high of $21.31.

KalVista Pharmaceuticals News Summary

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Analysts have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), which supports upside expectations relative to the current price. Read More.
• Positive Sentiment: Large institutional buying reported in recent quarters (Vanguard, State Street, Tudor, Vestal Point, Parkman Healthcare) signals conviction from long?term investors and can underpin the stock if fundamentals progress. Read More.
• Neutral Sentiment: Company fundamentals and technicals are supportive: strong liquidity (high current/quick ratios) and the 50?day/200?day moving averages sit below recent trades — helpful background but not an immediate catalyst.
• Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares; CFO Brian Piekos and others sold smaller blocks). Filings state the sales were to cover tax withholding on vested awards, but the concentrated insider selling is creating near?term downward pressure and investor concern. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KALV. Needham & Company LLC increased their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Citizens Jmp reduced their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 26th. Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright increased their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KALV. AQR Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the 1st quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after buying an additional 2,939 shares during the period. Goldman Sachs Group Inc. raised its position in shares of KalVista Pharmaceuticals by 3.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after buying an additional 12,263 shares during the period. Creative Planning raised its position in shares of KalVista Pharmaceuticals by 20.0% in the 2nd quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company’s stock worth $377,000 after buying an additional 5,573 shares during the period. Finally, Rhumbline Advisers raised its position in shares of KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.